



Harmony Biosciences Q1 2021 Financial and Business Update

May 11, 2021




Legal Disclaimer

This presentation includes forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 25, 2021 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.


This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Harmony's Strategy for Growth



Q1 2021 WAKIX Revenue Performance

Continued Growth with Q1 Revenue of \$59.7M



1Q20	4Q20	1Q21	1Q21 vs. 4Q20	1Q21 vs. 1Q20
\$19.8	\$56.3	\$59.7	6%	201%

Strong Revenue Growth in Q1 2021

- Over 200% growth Q1 2021 vs. Q1 2020
- Continued sequential quarter over quarter growth from Q4 2020 to Q1 2021

Driving Growth Through Our Launch For WAKIX

Q1 2021 Performance



Patient Outreach Programs & Support

~2,800

Average # of WAKIX Patients



Expanded Virtual Engagement Programs

>2,700

Unique HCP Prescribers Since Launch



Healthcare Professional Educational Initiatives


~80%

U.S. Covered Lives With Formulary Access



Managed Care Education & Outreach

Core Attributes of WAKIX Product Profile Align with Existing Unmet Needs in Narcolepsy




* Based on FDA approved product labeling


Source: Harmony ATU, July 2018 (n=286); Versta Research, Know Narcolepsy Survey ("Know Narcolepsy"), October 2018

HCP Insights Demonstrate Future Growth Opportunity for WAKIX in Adult Narcolepsy


Key Findings from HCP Market Research:



Significant unmet need and WAKIX offers a unique treatment option for patients



WAKIX is effective for treatment of EDS and 90% effective for cataplexy



Expecting to prescribe the same or increase their use of WAKIX in more patients in the future

- WAKIX is being **well received by patients**
- WAKIX is **appropriate for the vast majority** of narcolepsy patients
 - **Patient opportunity increased since the approval for the cataplexy indication**

Demonstrates the overall benefit/risk profile, broad clinical utility to narcolepsy patients

Source: Harmony Market Research conducted with 50 narcolepsy treating HCPs, April 2021 (n=50)

Patient Insights Demonstrate Future Growth Opportunity for WAKIX

Key Findings from Patient Market Research:

- Patients communicated an **overall good experience with WAKIX**
- **Better experience in learning about and accessing the medication** than other narcolepsy treatments



Patient's **interest in WAKIX is strong** and has increased since the cataplexy indication



Likely to tell other people living with narcolepsy about WAKIX



WAKIX users **expect to continue to take WAKIX**

Source: Harmony Market Research conducted with 30 narcolepsy patients with WAKIX experience, April 2021 (n=30)

Multiple Opportunities for Pitolisant

Indication	Pre-IND	Phase 1	Phase 2	Phase 3	Regulatory Filing ¹	Marketed Product	Upcoming Milestones
APPROVED INDICATIONS							
EDS in Adult Patients with Narcolepsy	[Green arrow spanning Pre-IND to Marketed Product]						
Cataplexy in Adult Patients with Narcolepsy	[Green arrow spanning Pre-IND to Marketed Product]						
LABEL EXPANSION IN NARCOLEPSY							
Pediatric Narcolepsy ²	[Light green arrow spanning Pre-IND to Phase 3]						
NEW INDICATIONS							
Prader-Willi Syndrome	[Blue arrow spanning Pre-IND to Phase 2]						Top line data 1H2022
Myotonic Dystrophy	[Blue arrow spanning Pre-IND to Phase 2]						IND open; initiation of Phase 2 trial 1H2021; top line data 2H2022


1. Includes New Drug Applications and supplemental New Drug Applications.

2. Current trial being conducted by Bioprojet.


WAKIX: Effective in Patients with High Burden of Narcolepsy Symptoms

- Post-hoc analyses of pooled data from pivotal randomized controlled trials (HARMONY 1 and HARMONY CTP)
- Assessed response to WAKIX compared to placebo in patients who had a high burden of EDS (ESS ≥ 16) or cataplexy (weekly rate of cataplexy attacks ≥ 15) at baseline

Epworth Sleepiness Scale (ESS) Scores



Weekly Rate of Cataplexy (WRC)



WAKIX was significantly more effective on improving EDS compared with placebo; mean change in ESS from baseline to end of treatment was -6.1 for WAKIX compared with -2.4 for placebo ($p < 0.001$)

WAKIX was significantly more effective on reducing the WRC compared with placebo; mean change in WRC from baseline to end of treatment was -14.5 for WAKIX compared with -0.1 for placebo ($p < 0.004$)

WAKIX: Onset of Effect Beginning at Week 2

- Post-hoc analyses of pooled data from pivotal randomized controlled trials (HARMONY 1 and HARMONY CTP)
- Assessed time-to-onset of response for WAKIX compared to placebo from baseline to end of trial

Figure 1. Epworth Sleepiness Scale Scores

A. Harmony 1





Figure 2: WRC in Harmony CTP



Conclusions:

- WAKIX was effective for improvement in EDS and reduction in cataplexy **beginning at week 2 after dosing**
- Clinical response at the end of the study was more robust when patients were titrated up to the 35.6 mg dose compared to 17.8 mg dose

Q1 2021 Financial Summary *(in millions, USD)*

	Three Months Ended March 31,	
	2021	2020
Net Product Revenues	\$ 59.7	\$ 19.8
Cost of Product Sold	10.4	3.5
Total Operating Expenses	\$ 34.7	\$ 26.0
R&D Expense	4.7	3.4
S&M Expense	15.5	13.3
G&A Expense	14.5	9.3
Net Income (Loss)	\$ 7.4	\$ (38.6)
Cash & cash equivalents	\$ 141.2	

GAAP vs Non-GAAP Reconciliation *(in millions, USD)*

	Three Months Ended March 31,	
	2021	2020
GAAP reported net income (loss)	\$ 7.4	\$ (38.6)
Interest expense / income	7.1	6.4
Taxes		
Depreciation	0.1	0.1
Amortization	4.6	1.8
EBITDA	19.2	(30.4)
Stock-based compensation expense	3.3	0.4
Loss on debt extinguishment		22.6
Warrant expense		1.1
Non-GAAP adjusted net income (loss)	22.4	(6.2)
Accumulation of yield on preferred stock		(10.4)
Non-GAAP adjusted net income (loss) available to common stockholders	\$ 22.4	\$ (16.7)
GAAP reported net loss per diluted share	\$ 0.13	\$ (6.30)
Non-GAAP adjusted net income (loss) per diluted share	\$ 0.38	\$ (2.14)
Weighted average number of shares of common stock used in non-GAAP diluted per share	58,805,285	7,790,667

Totals may not foot due to rounding



Thank You

May 11, 2021

